Vancomycin resistance in staphylococci

被引:172
作者
Srinivasan, A
Dick, JD
Perl, TM
机构
[1] Johns Hopkins Med Inst, Dept Internal Med, Div Infect Dis, Baltimore, MD 21205 USA
[2] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA
关键词
D O I
10.1128/CMR.15.3.430-438.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Vancomycin resistance has been reported in clinical isolates of both coagulase-negative staphylococci and Staphylococcus aureus. The emerging threat of widespread vancomycin resistance poses a serious public health concern given the fact that vancomycin has long been the preferred treatment of antibiotic-resistant gram-positive organisms. Though major efforts are now being focused on improving our understanding of vancomycin resistance, there is much that remains unknown at this time. This article reviews the major epidemiologic, microbiologic, and clinical characteristics of vancomycin resistance in both coagulase-negative staphylococci and S. aureus. The review begins with a discussion of issues common to both coagulase-negative staphylococci and S. aureus, such as definitions, laboratory detection of vancomycin resistance, and infection control issues related to vancomycin-resistant staphylococci. The rest of the article is then devoted to a discussion of issues unique to each organism, including epidemiology, risk factors for infection, mechanisms of resistance, and management options.
引用
收藏
页码:430 / +
页数:10
相关论文
共 85 条
[11]   OUTBREAK OF MULTIDRUG-RESISTANT ENTEROCOCCUS-FAECIUM WITH TRANSFERABLE VANB CLASS VANCOMYCIN RESISTANCE [J].
BOYCE, JM ;
OPAL, SM ;
CHOW, JW ;
ZERVOS, MJ ;
POTTERBYNOE, G ;
SHERMAN, CB ;
ROMULO, RLC ;
FORTNA, S ;
MEDEIROS, AA .
JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (05) :1148-1153
[12]  
Boyce JM, 1997, INFECT CONT HOSP EP, V18, P622
[13]   MOLECULAR-BASIS FOR VANCOMYCIN RESISTANCE IN ENTEROCOCCUS-FAECIUM BM4147 - BIOSYNTHESIS OF A DEPSIPEPTIDE PEPTIDOGLYCAN PRECURSOR BY VANCOMYCIN RESISTANCE PROTEINS VANH AND VANA [J].
BUGG, TDH ;
WRIGHT, GD ;
DUTKAMALEN, S ;
ARTHUR, M ;
COURVALIN, P ;
WALSH, CT .
BIOCHEMISTRY, 1991, 30 (43) :10408-10415
[14]  
*CDCP, 2000, MMWR-MORBID MORTAL W, V48, P1167
[15]  
Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P626
[16]  
Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V48, P1165
[17]   Combinations of vancomycin and β-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin [J].
Climo, MW ;
Patron, RL ;
Archer, GL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) :1747-1753
[18]   CHARACTERIZATION OF STAPHYLOCOCCUS-AUREUS ISOLATES WITH DECREASED SUSCEPTIBILITY TO VANCOMYCIN AND TEICOPLANIN - ISOLATION AND PURIFICATION OF A CONSTITUTIVELY PRODUCED PROTEIN ASSOCIATED WITH DECREASED SUSCEPTIBILITY [J].
DAUM, RS ;
GUPTA, S ;
SABBAGH, R ;
MILEWSKI, WM .
JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (05) :1066-1072
[19]   Resistance of staphylococci in The Netherlands: surveillance by an electronic network during 1989-1995 [J].
de Neeling, AJ ;
van Leeuwen, WJ ;
Schouls, LM ;
Schot, CS ;
van Veen-Rutgers, A ;
Beunders, AJ ;
Buiting, AGM ;
Hol, C ;
Ligtvoet, EEJ ;
Petit, PL ;
Sabbe, LJM ;
van Griethuysen, AJA ;
van Embden, JDA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (01) :93-101
[20]   Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides [J].
Del'Alamo, L ;
Cereda, RF ;
Tosin, I ;
Miranda, EA ;
Sader, HS .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 34 (03) :185-191